NO324564B1 - Anvendelse av ET743 for fremstilling av et medikament for behandling av kreft - Google Patents
Anvendelse av ET743 for fremstilling av et medikament for behandling av kreft Download PDFInfo
- Publication number
- NO324564B1 NO324564B1 NO20015516A NO20015516A NO324564B1 NO 324564 B1 NO324564 B1 NO 324564B1 NO 20015516 A NO20015516 A NO 20015516A NO 20015516 A NO20015516 A NO 20015516A NO 324564 B1 NO324564 B1 NO 324564B1
- Authority
- NO
- Norway
- Prior art keywords
- cancer
- administered
- patients
- dose
- treatment
- Prior art date
Links
- PKVRCIRHQMSYJX-AIFWHQITSA-N trabectedin Chemical compound C([C@@]1(C(OC2)=O)NCCC3=C1C=C(C(=C3)O)OC)S[C@@H]1C3=C(OC(C)=O)C(C)=C4OCOC4=C3[C@H]2N2[C@@H](O)[C@H](CC=3C4=C(O)C(OC)=C(C)C=3)N(C)[C@H]4[C@@H]21 PKVRCIRHQMSYJX-AIFWHQITSA-N 0.000 title claims description 48
- 239000003814 drug Substances 0.000 title claims description 30
- 206010028980 Neoplasm Diseases 0.000 title claims description 27
- 201000011510 cancer Diseases 0.000 title claims description 24
- 229940079593 drug Drugs 0.000 title claims description 23
- 238000004519 manufacturing process Methods 0.000 title claims description 5
- 238000011282 treatment Methods 0.000 title abstract description 36
- 238000001802 infusion Methods 0.000 claims description 26
- 238000001990 intravenous administration Methods 0.000 claims description 12
- 238000002512 chemotherapy Methods 0.000 claims description 9
- 206010006187 Breast cancer Diseases 0.000 claims description 8
- 208000026310 Breast neoplasm Diseases 0.000 claims description 7
- 201000008968 osteosarcoma Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 208000028210 stromal sarcoma Diseases 0.000 claims description 3
- 208000018142 Leiomyosarcoma Diseases 0.000 claims description 2
- 206010027406 Mesothelioma Diseases 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims description 2
- 230000006872 improvement Effects 0.000 claims description 2
- 206010024627 liposarcoma Diseases 0.000 claims description 2
- 201000002575 ocular melanoma Diseases 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 21
- 201000010099 disease Diseases 0.000 abstract description 19
- 150000001875 compounds Chemical class 0.000 abstract description 12
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000024770 Thyroid neoplasm Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000003532 hypothyroidism Diseases 0.000 abstract 1
- 230000002989 hypothyroidism Effects 0.000 abstract 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000002510 thyroid cancer Diseases 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 description 18
- 229960000977 trabectedin Drugs 0.000 description 18
- 238000000034 method Methods 0.000 description 17
- 206010039491 Sarcoma Diseases 0.000 description 14
- XXPXYPLPSDPERN-UHFFFAOYSA-N Ecteinascidin 743 Natural products COc1cc2C(NCCc2cc1O)C(=O)OCC3N4C(O)C5Cc6cc(C)c(OC)c(O)c6C(C4C(S)c7c(OC(=O)C)c(C)c8OCOc8c37)N5C XXPXYPLPSDPERN-UHFFFAOYSA-N 0.000 description 13
- 239000000203 mixture Substances 0.000 description 11
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 10
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 8
- 231100000419 toxicity Toxicity 0.000 description 8
- 230000001988 toxicity Effects 0.000 description 8
- 230000004044 response Effects 0.000 description 7
- 241000798369 Ecteinascidia turbinata Species 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 206010061289 metastatic neoplasm Diseases 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 4
- 229960003957 dexamethasone Drugs 0.000 description 4
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 206010025323 Lymphomas Diseases 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 229940045799 anthracyclines and related substance Drugs 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 3
- 230000001394 metastastic effect Effects 0.000 description 3
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- -1 taxotes Chemical compound 0.000 description 3
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 description 2
- 208000001382 Experimental Melanoma Diseases 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000002111 antiemetic agent Substances 0.000 description 2
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 206010006007 bone sarcoma Diseases 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 231100000026 common toxicity Toxicity 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000003978 infusion fluid Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 208000011932 ovarian sarcoma Diseases 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000006257 total synthesis reaction Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- XQZOGOCTPKFYKC-VSZULPIASA-N (2r)-n-[(3s,6s,8s,12s,13r,16s,17r,20s,23s)-13-[(2s)-butan-2-yl]-12-hydroxy-20-[(4-methoxyphenyl)methyl]-6,17,21-trimethyl-3-(2-methylpropyl)-2,5,7,10,15,19,22-heptaoxo-8-propan-2-yl-9,18-dioxa-1,4,14,21-tetrazabicyclo[21.3.0]hexacosan-16-yl]-4-methyl-2-(m Chemical compound C([C@H]1C(=O)O[C@H](C)[C@H](NC(=O)[C@@H](CC(C)C)NC)C(=O)N[C@@H]([C@H](CC(=O)O[C@H](C(=O)[C@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N1C)C(C)C)O)[C@@H](C)CC)C1=CC=C(OC)C=C1 XQZOGOCTPKFYKC-VSZULPIASA-N 0.000 description 1
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 108010016076 Octreotide Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229930190585 Saframycin Natural products 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 101100537665 Trypanosoma cruzi TOR gene Proteins 0.000 description 1
- 241000251555 Tunicata Species 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000002927 anti-mitotic effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940124691 antibody therapeutics Drugs 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940045686 antimetabolites antineoplastic purine analogs Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 229930189582 didemnin Natural products 0.000 description 1
- 108010061297 didemnins Proteins 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 230000005918 in vitro anti-tumor Effects 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 201000010893 malignant breast melanoma Diseases 0.000 description 1
- 231100001142 manageable toxicity Toxicity 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 1
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229960002700 octreotide Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 108010049948 plitidepsin Proteins 0.000 description 1
- UUSZLLQJYRSZIS-LXNNNBEUSA-N plitidepsin Chemical compound CN([C@H](CC(C)C)C(=O)N[C@@H]1C(=O)N[C@@H]([C@H](CC(=O)O[C@H](C(=O)[C@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(OC)=CC=2)C(=O)O[C@@H]1C)C(C)C)O)[C@@H](C)CC)C(=O)[C@@H]1CCCN1C(=O)C(C)=O UUSZLLQJYRSZIS-LXNNNBEUSA-N 0.000 description 1
- 229950008499 plitidepsin Drugs 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000000561 purinyl group Chemical class N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- JNEGMBHBUAJRSX-SHUHUVMISA-N saframycin a Chemical compound C([C@H](N1C)[C@@H]2C#N)C(C(C(C)=C(OC)C3=O)=O)=C3[C@@H]1[C@H](C1)N2[C@@H](CNC(=O)C(C)=O)C2=C1C(=O)C(C)=C(OC)C2=O JNEGMBHBUAJRSX-SHUHUVMISA-N 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000002356 skeleton Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical class C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 239000003744 tubulin modulator Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9911183.3A GB9911183D0 (en) | 1999-05-13 | 1999-05-13 | Treatment of cancers |
GBGB9911346.6A GB9911346D0 (en) | 1999-05-14 | 1999-05-14 | Treatment of cancers |
GBGB9918534.0A GB9918534D0 (en) | 1999-08-05 | 1999-08-05 | Treatment of cancers |
GBGB9927005.0A GB9927005D0 (en) | 1999-11-15 | 1999-11-15 | Treatment of cancers |
GBGB9927106.6A GB9927106D0 (en) | 1999-11-16 | 1999-11-16 | Cancer treatment |
GB0007637A GB0007637D0 (en) | 2000-03-29 | 2000-03-29 | Antitumour compound |
PCT/GB2000/001857 WO2000069441A1 (en) | 1999-05-13 | 2000-05-15 | Compositions and uses of et743 for treating cancer |
Publications (3)
Publication Number | Publication Date |
---|---|
NO20015516D0 NO20015516D0 (no) | 2001-11-12 |
NO20015516L NO20015516L (no) | 2002-01-11 |
NO324564B1 true NO324564B1 (no) | 2007-11-19 |
Family
ID=27546594
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20015516A NO324564B1 (no) | 1999-05-13 | 2001-11-12 | Anvendelse av ET743 for fremstilling av et medikament for behandling av kreft |
NO2008005C NO2008005I1 (no) | 1999-05-13 | 2008-05-16 | Trabectedin |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO2008005C NO2008005I1 (no) | 1999-05-13 | 2008-05-16 | Trabectedin |
Country Status (32)
Country | Link |
---|---|
US (1) | US8119638B2 (ru) |
EP (3) | EP1176964B8 (ru) |
JP (2) | JP2002544231A (ru) |
KR (1) | KR20020019914A (ru) |
CN (2) | CN1360503A (ru) |
AR (1) | AR028476A1 (ru) |
AT (3) | ATE338552T1 (ru) |
AU (2) | AU777417B2 (ru) |
BG (1) | BG65680B1 (ru) |
BR (1) | BR0010531A (ru) |
CA (1) | CA2373794C (ru) |
CY (4) | CY1105818T1 (ru) |
CZ (1) | CZ301482B6 (ru) |
DE (4) | DE60045720D1 (ru) |
DK (3) | DK1176964T3 (ru) |
ES (2) | ES2294756T3 (ru) |
FR (1) | FR08C0013I2 (ru) |
HU (2) | HU229866B1 (ru) |
IL (2) | IL146434A0 (ru) |
LU (1) | LU91418I2 (ru) |
MX (1) | MXPA01011562A (ru) |
MY (1) | MY164077A (ru) |
NL (1) | NL300337I2 (ru) |
NO (2) | NO324564B1 (ru) |
NZ (1) | NZ515423A (ru) |
PL (1) | PL198185B1 (ru) |
PT (3) | PT1716853E (ru) |
SI (3) | SI1716853T1 (ru) |
SK (1) | SK287580B6 (ru) |
TR (1) | TR200103819T2 (ru) |
UA (1) | UA74782C2 (ru) |
WO (1) | WO2000069441A1 (ru) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY164077A (en) | 1999-05-13 | 2017-11-30 | Pharma Mar Sa | Compositions and uses of et743 for treating cancer |
MXPA02011319A (es) | 2000-05-15 | 2003-06-06 | Pharma Mar Sa | Analogos antitumorales de ecteinascidina 743. |
CZ20031327A3 (cs) * | 2000-11-06 | 2003-11-12 | Pharma Mar, S. A. | Užití ET-743 k výrobě léků pro účinnou protinádorovou léčbu |
GB0117402D0 (en) * | 2001-07-17 | 2001-09-05 | Pharma Mar Sa | New antitumoral derivatives of et-743 |
CA2462502A1 (en) * | 2001-10-19 | 2003-05-15 | Pharma Mar, S.A. | Improved use of antitumoral compound in cancer therapy |
GB0202544D0 (en) | 2002-02-04 | 2002-03-20 | Pharma Mar Sa | The synthesis of naturally occuring ecteinascidins and related compounds |
GB0324201D0 (en) * | 2003-10-15 | 2003-11-19 | Pharma Mar Sau | Improved antitumoral combinations |
CA2544320A1 (en) * | 2003-11-13 | 2005-06-02 | Pharma Mar, S.A.U. | Method of treating cancer using a combination comprising et-743 and 5-fluorouracil |
CN1897949A (zh) * | 2003-11-14 | 2007-01-17 | 马尔药品公司 | 包含使用et-743和紫杉醇来治疗癌症的联合疗法 |
GB0326486D0 (en) * | 2003-11-14 | 2003-12-17 | Pharma Mar Sau | Combination treatment |
WO2006005602A2 (en) * | 2004-07-09 | 2006-01-19 | Pharma Mar, S.A. | Use of ecteinascidin in the treatment of cancer in patients with low level of brca1 |
SI1827500T1 (sl) * | 2004-10-26 | 2009-10-31 | Pharma Mar Sa | Pegiliran liposomski doksorubicin v kombinaciji s ekteinescidinom 743 |
SI1658848T1 (sl) * | 2004-10-29 | 2007-12-31 | Pharma Mar Sa | Formulacije vsebujoäśe ekteinascidin in disaharid |
GB0522082D0 (en) * | 2005-10-31 | 2005-12-07 | Pharma Mar Sa | Formulations |
EP2023931A2 (en) * | 2006-05-12 | 2009-02-18 | Pharma Mar S.A. | Anticancer treatments with a combination of docetaxel and ecteinascidin |
AU2008313634A1 (en) * | 2007-10-19 | 2009-04-23 | Pharma Mar, S.A. | Prognostic molecular markers for ET-743 treatment |
AU2017215603A1 (en) * | 2016-02-04 | 2018-08-09 | Jiangsu Hengrui Medicine Co., Ltd. | Trabectedin-inclusive injectable pharmaceutical composition for gastrointestinal external use and method for manufacturing the same |
JOP20190254A1 (ar) | 2017-04-27 | 2019-10-27 | Pharma Mar Sa | مركبات مضادة للأورام |
WO2020239478A1 (en) | 2019-05-28 | 2020-12-03 | Pharma Mar, S.A. | Trabectedin for treating sarcomas based on genomic markers |
CN112574234B (zh) * | 2019-09-27 | 2022-05-24 | 江苏恒瑞医药股份有限公司 | 一种海鞘素衍生物的制备方法 |
AU2021256746A1 (en) | 2020-04-15 | 2022-11-03 | Ever Valinject Gmbh | Composition comprising trabectedin and an amino acid |
US20230226051A1 (en) | 2022-01-20 | 2023-07-20 | Extrovis Ag | Trabectedin composition |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5089273A (en) | 1986-06-09 | 1992-02-18 | Board Of Trustees Of The University Of Illinois | Ecteinascidins 729, 743, 745, 759A, 759B and 770 |
JP2562162B2 (ja) * | 1986-06-09 | 1996-12-11 | ユニバーシティ・オブ・イリノイ | エクテインアシジン729、743、745、759a、759bおよび770 |
US5256663A (en) * | 1986-06-09 | 1993-10-26 | The Board Of Trustees Of The University Of Illinois | Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith |
US5149804A (en) * | 1990-11-30 | 1992-09-22 | The Board Of Trustees Of The University Of Illinois | Ecteinascidins 736 and 722 |
DE3635711A1 (de) * | 1986-10-21 | 1988-04-28 | Knoll Ag | 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung |
GB8805268D0 (en) * | 1988-03-04 | 1988-04-07 | Glaxo Group Ltd | Medicaments |
GB9101221D0 (en) * | 1991-01-19 | 1991-02-27 | Smithkline Beecham Plc | Pharmaceuticals |
US5721352A (en) | 1991-02-19 | 1998-02-24 | University Of Florida Research Foundation | Entomopoxvirus expression system |
FR2697752B1 (fr) * | 1992-11-10 | 1995-04-14 | Rhone Poulenc Rorer Sa | Compositions antitumorales contenant des dérivés du taxane. |
US5891704A (en) * | 1992-11-19 | 1999-04-06 | Anticancer, Inc. | Method to produce high levels of methioninase |
WO1994026250A1 (en) * | 1993-05-14 | 1994-11-24 | Depotech Corporation | Method for treating neurological disorders |
US5478932A (en) * | 1993-12-02 | 1995-12-26 | The Board Of Trustees Of The University Of Illinois | Ecteinascidins |
US20040059112A1 (en) * | 1994-02-18 | 2004-03-25 | Rinehart Kenneth L. | Ecteinascidins |
US5919816A (en) * | 1994-11-14 | 1999-07-06 | Bionumerik Pharmaceuticals, Inc. | Formulations and methods of reducing toxicity of antineoplastic agents |
GB9508195D0 (en) * | 1995-04-20 | 1995-06-07 | Univ British Columbia | Novel biologically active compounds and compositions,their use and derivation |
US5721362A (en) * | 1996-09-18 | 1998-02-24 | President And Fellows Of Harvard College | Process for producing ecteinascidin compounds |
ATE305301T1 (de) * | 1996-11-05 | 2005-10-15 | Childrens Medical Center | Mittel zur hemmung von angiogenese enthaltend thalodomid und einen nsaid |
IL123740A0 (en) * | 1997-03-28 | 1998-10-30 | Pfizer | NK-1 receptor antagonists for the treatment of delayed emesis |
US5985876A (en) * | 1997-04-15 | 1999-11-16 | Univ Illinois | Nucleophile substituted ecteinascidins and N-oxide ecteinascidins |
DE19720312A1 (de) * | 1997-05-15 | 1998-11-19 | Hoechst Ag | Zubereitung mit erhöhter in vivo Verträglichkeit |
GB9801231D0 (en) * | 1997-06-05 | 1998-03-18 | Merck & Co Inc | A method of treating cancer |
US6124293A (en) * | 1998-04-06 | 2000-09-26 | The Board Of Trustees Of The University Of Illinois | Semi-synthetic ecteinascidins |
ES2239442T3 (es) * | 1998-05-11 | 2005-09-16 | Pharma Mar, S.A. | Metabolitos de ecteinascidina 743. |
US6124292A (en) * | 1998-09-30 | 2000-09-26 | President And Fellows Of Harvard College | Synthetic analogs of ecteinascidin-743 |
MY164077A (en) | 1999-05-13 | 2017-11-30 | Pharma Mar Sa | Compositions and uses of et743 for treating cancer |
MY130271A (en) * | 1999-05-14 | 2007-06-29 | Pharma Mar Sa | Hemisynthetic method and new compounds |
PT1280809E (pt) | 2000-04-12 | 2005-11-30 | Pharma Mar Sa | Derivados antitumorais de ecteinascidina |
US7247892B2 (en) * | 2000-04-24 | 2007-07-24 | Taylor Geoff W | Imaging array utilizing thyristor-based pixel elements |
US7420051B2 (en) * | 2000-05-15 | 2008-09-02 | Pharma Mar, S.A. | Synthetic process for the manufacture of an ecteinaschidin compound |
MXPA02011319A (es) * | 2000-05-15 | 2003-06-06 | Pharma Mar Sa | Analogos antitumorales de ecteinascidina 743. |
EP1356097A2 (en) * | 2000-08-11 | 2003-10-29 | City of Hope | The anti-neoplastic agent et-743 inhibits trans activation by sxr |
CZ20031327A3 (cs) | 2000-11-06 | 2003-11-12 | Pharma Mar, S. A. | Užití ET-743 k výrobě léků pro účinnou protinádorovou léčbu |
EP1360337A1 (en) | 2001-02-09 | 2003-11-12 | The Regents Of The University Of California | Ecteinascidin family compounds: compositions and methods |
WO2002078678A2 (en) | 2001-03-30 | 2002-10-10 | Shire Biochem Inc. | Methods of treating cancer using cyplastin combined with a dioxolane nucleoside such as troxacitabine |
GB0121285D0 (en) | 2001-09-03 | 2001-10-24 | Cancer Res Ventures Ltd | Anti-cancer combinations |
CA2462502A1 (en) | 2001-10-19 | 2003-05-15 | Pharma Mar, S.A. | Improved use of antitumoral compound in cancer therapy |
US20040019027A1 (en) * | 2002-04-12 | 2004-01-29 | Barry Forman | Method of treating cerebrotendinous xanthomatosis |
GB0312407D0 (en) * | 2003-05-29 | 2003-07-02 | Pharma Mar Sau | Treatment |
GB0324201D0 (en) * | 2003-10-15 | 2003-11-19 | Pharma Mar Sau | Improved antitumoral combinations |
CA2544320A1 (en) * | 2003-11-13 | 2005-06-02 | Pharma Mar, S.A.U. | Method of treating cancer using a combination comprising et-743 and 5-fluorouracil |
CN1897949A (zh) * | 2003-11-14 | 2007-01-17 | 马尔药品公司 | 包含使用et-743和紫杉醇来治疗癌症的联合疗法 |
GB0326486D0 (en) | 2003-11-14 | 2003-12-17 | Pharma Mar Sau | Combination treatment |
WO2006005602A2 (en) * | 2004-07-09 | 2006-01-19 | Pharma Mar, S.A. | Use of ecteinascidin in the treatment of cancer in patients with low level of brca1 |
CN101068596A (zh) * | 2004-09-29 | 2007-11-07 | 法马马私人股份有限公司 | 艾可特耐思地作抗炎药 |
SI1827500T1 (sl) | 2004-10-26 | 2009-10-31 | Pharma Mar Sa | Pegiliran liposomski doksorubicin v kombinaciji s ekteinescidinom 743 |
SI1658848T1 (sl) * | 2004-10-29 | 2007-12-31 | Pharma Mar Sa | Formulacije vsebujoäśe ekteinascidin in disaharid |
US20090170860A1 (en) * | 2005-11-25 | 2009-07-02 | Pharma Mar, S.A., Sociedad Unipersonal | Use of PARP-1 Inhibitors |
EP2023931A2 (en) * | 2006-05-12 | 2009-02-18 | Pharma Mar S.A. | Anticancer treatments with a combination of docetaxel and ecteinascidin |
-
2000
- 2000-05-13 MY MYPI20002107A patent/MY164077A/en unknown
- 2000-05-15 DE DE60045720T patent/DE60045720D1/de not_active Expired - Lifetime
- 2000-05-15 DE DE60030554T patent/DE60030554T8/de active Active
- 2000-05-15 WO PCT/GB2000/001857 patent/WO2000069441A1/en active IP Right Grant
- 2000-05-15 PT PT06014005T patent/PT1716853E/pt unknown
- 2000-05-15 EP EP00927584A patent/EP1176964B8/en not_active Expired - Lifetime
- 2000-05-15 ES ES06011784T patent/ES2294756T3/es not_active Expired - Lifetime
- 2000-05-15 PL PL352931A patent/PL198185B1/pl unknown
- 2000-05-15 EP EP06011784A patent/EP1702618B1/en not_active Expired - Lifetime
- 2000-05-15 DE DE60036826T patent/DE60036826T2/de not_active Expired - Lifetime
- 2000-05-15 AT AT00927584T patent/ATE338552T1/de active
- 2000-05-15 SI SI200031067T patent/SI1716853T1/sl unknown
- 2000-05-15 AT AT06011784T patent/ATE375795T1/de active
- 2000-05-15 DE DE122008000013C patent/DE122008000013I1/de active Pending
- 2000-05-15 TR TR2001/03819T patent/TR200103819T2/xx unknown
- 2000-05-15 SI SI200030905T patent/SI1176964T1/sl unknown
- 2000-05-15 CN CN00809976A patent/CN1360503A/zh active Pending
- 2000-05-15 CA CA002373794A patent/CA2373794C/en not_active Expired - Lifetime
- 2000-05-15 UA UA2001128559A patent/UA74782C2/ru unknown
- 2000-05-15 DK DK00927584T patent/DK1176964T3/da active
- 2000-05-15 ES ES00927584T patent/ES2272279T3/es not_active Expired - Lifetime
- 2000-05-15 AT AT06014005T patent/ATE500830T1/de active
- 2000-05-15 PT PT06011784T patent/PT1702618E/pt unknown
- 2000-05-15 BR BR0010531-7A patent/BR0010531A/pt not_active Application Discontinuation
- 2000-05-15 DK DK06011784T patent/DK1702618T3/da active
- 2000-05-15 KR KR1020017014479A patent/KR20020019914A/ko active Search and Examination
- 2000-05-15 JP JP2000617900A patent/JP2002544231A/ja not_active Withdrawn
- 2000-05-15 NZ NZ515423A patent/NZ515423A/en not_active IP Right Cessation
- 2000-05-15 SK SK1644-2001A patent/SK287580B6/sk not_active IP Right Cessation
- 2000-05-15 HU HU0201187A patent/HU229866B1/hu active Protection Beyond IP Right Term
- 2000-05-15 SI SI200030977T patent/SI1702618T1/sl unknown
- 2000-05-15 AU AU45975/00A patent/AU777417B2/en not_active Expired
- 2000-05-15 CZ CZ20014081A patent/CZ301482B6/cs not_active IP Right Cessation
- 2000-05-15 AR ARP000102321A patent/AR028476A1/es not_active Application Discontinuation
- 2000-05-15 EP EP06014005A patent/EP1716853B9/en not_active Expired - Lifetime
- 2000-05-15 DK DK06014005.0T patent/DK1716853T3/da active
- 2000-05-15 MX MXPA01011562A patent/MXPA01011562A/es active IP Right Grant
- 2000-05-15 PT PT00927584T patent/PT1176964E/pt unknown
- 2000-05-15 CN CNB2005100091622A patent/CN100477993C/zh not_active Expired - Lifetime
- 2000-05-15 IL IL14643400A patent/IL146434A0/xx active IP Right Grant
-
2001
- 2001-11-11 IL IL146434A patent/IL146434A/en active Protection Beyond IP Right Term
- 2001-11-12 NO NO20015516A patent/NO324564B1/no not_active IP Right Cessation
- 2001-12-03 BG BG106171A patent/BG65680B1/bg unknown
-
2005
- 2005-01-14 AU AU2005200180A patent/AU2005200180B9/en not_active Expired
-
2006
- 2006-11-30 CY CY20061101734T patent/CY1105818T1/el unknown
-
2007
- 2007-06-28 US US11/769,873 patent/US8119638B2/en not_active Expired - Fee Related
-
2008
- 2008-01-16 CY CY20081100059T patent/CY1107143T1/el unknown
- 2008-02-22 NL NL300337C patent/NL300337I2/nl unknown
- 2008-03-10 LU LU91418C patent/LU91418I2/fr unknown
- 2008-04-07 CY CY200800007C patent/CY2008007I1/el unknown
- 2008-04-16 FR FR08C0013C patent/FR08C0013I2/fr active Active
- 2008-05-16 NO NO2008005C patent/NO2008005I1/no not_active IP Right Cessation
-
2011
- 2011-06-08 CY CY20111100545T patent/CY1112753T1/el unknown
-
2012
- 2012-05-02 JP JP2012105249A patent/JP5777562B2/ja not_active Expired - Lifetime
-
2015
- 2015-01-06 HU HUS1500001C patent/HUS1500001I1/hu unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8119638B2 (en) | Compositions and uses of ET743 for treating cancer | |
AU2002343548B8 (en) | Improved use of antitumoral compound in cancer therapy | |
AU2002343548A1 (en) | Improved use of antitumoral compound in cancer therapy | |
MXPA02004862A (es) | Tratamiento de aplidina para canceres. | |
MXPA03003230A (es) | Tratamiento de canceres. | |
RU2266734C2 (ru) | Композиции и применение ет743 для лечения злокачественных опухолей | |
NZ529801A (en) | Compositions and uses of ET743 for treating cancer | |
ES2363064T3 (es) | Tratamiento de cánceres del cuerpo humano utilizando et743. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
SPCF | Filing of supplementary protection certificate |
Free format text: PRODUCT NAME: YONDELIS 0,25 MG PULVER TIL KONSENTRAT TIL INFUSJONSVAESKE, OPPLOESNING "PHARMA MAR" - 1 HETTEGLASS YONDELIS 1 MG PULVER TIL KONSENTRAT TIL INFUSJONSVAESKE, OPPLOESNING "PHARMA MAR" - 1 HETTEGLASS; NAT. REG. NO/DATE: EU/1/07/417/001 20071023; FIRST REG. NO/DATE: EU , EU/1/07/417/001 20070920 Spc suppl protection certif: 2008005 Filing date: 20080516 |
|
SPCG | Granted supplementary protection certificate |
Free format text: PRODUCT NAME: YONDELIS 0,25 MG PULVER TIL KONSENTRAT TIL INFUSJONSVAESKE, OPPLOESNING "PHARMA MAR" - 1 HETTEGLASS YONDELIS 1 MG PULVER TIL KONSENTRAT TIL INFUSJONSVAESKE, OPPLOESNING "PHARMA MAR" - 1 HETTEGLASS; NAT. REG. NO/DATE: EU/1/07/417/001 20071023; FIRST REG. NO/DATE: EU , EU/1/07/417/001 20070920 Spc suppl protection certif: 2008005 Filing date: 20080516 Extension date: 20220920 |
|
SPCK | Change in the validity period of an spc |
Free format text: GYLDIGHETSPERIODEN FOR SPC 2008005 ER ENDRET ETTER BEGJAERING FRA SOEKER. GYLDIG T.OM.: 2022.09.20 Spc suppl protection certif: 2008005 |
|
MK1K | Patent expired | ||
SPCX | Expiry of an spc |
Spc suppl protection certif: 2008005 Expiry date: 20220920 |